Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 7, 2010, Pages 481-482

  Ceppi, P ^a   Monica, V ^a   Righi, L ^a   Papotti, M ^a   Scagliotti, G V ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Malignant pleural mesothelioma; Non small cell lung cancer; Pemetrexed; Small cell lung cancer; Thymidylate synthase

Indexed keywords

CISPLATIN; DESMOCOLLIN; DESMOCOLLIN 3; DIHYDROFOLATE REDUCTASE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLATINUM; PLATINUM DERIVATIVE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PATIENT SELECTION; PHARMACOGENOMICS; PLEURA MESOTHELIOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THORAX CANCER;

EID: 77954919591     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48481     Document Type: Conference Paper

References (9)

1. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997; 57: 1116-1123.
2. Rossi A, Ricciardi S, Maione Pet al. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 2009; 66: 141-149.
3. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009; 14: 253-263.
4. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
5. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006; 107: 1589-1596. (Pubitemid 44546920)
6. Socinski MA, Smit EF, Lorigan P et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009; 27: 4787-4792.
7. Ceppi P, Volante M, Ferrero A et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res. 2008; 14: 1059-1064. (Pubitemid 351302551)
8. Monica V, Scagliotti GV, Ceppi Pet al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res. 2009; 24: 7547-7552.
9. Righi L, Papotti MG, Ceppi P et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010; 9: 1534-1539.